Statement on PBL’s Royalty Bearing Licence Agreement with Jazz Pharmaceuticals

Following significant investment by its shareholder, PBL has been implementing a series of initiatives to increase capacity and better supply the market which we look forward to implementing.  As such, in the interests of pursuing better value for money, PBL has taken the decision to issue notice to Jazz Pharmaceuticals – which was allowed for in the contractual agreement – and explore alternative opportunities for the distribution of Erwinase. We look forward to continuing our positive working relationship with Jazz for the next two years while we seek via a competitive process, to secure a new partnership. Termination of this contract should have no impact on patients who receive this life saving drug.

09.00 Tuesday 12th February 2019

Any enquiries regarding this statement should be addressed to business@portonbiopharma.com